Guardant Health Inc (NASDAQ:GH) Expected to Announce Earnings of -$0.34 Per Share

Equities analysts expect Guardant Health Inc (NASDAQ:GH) to post earnings per share of ($0.34) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Guardant Health’s earnings, with the highest EPS estimate coming in at ($0.33) and the lowest estimate coming in at ($0.36). The firm is expected to report its next quarterly earnings results on Thursday, August 8th.

According to Zacks, analysts expect that Guardant Health will report full year earnings of ($1.48) per share for the current fiscal year, with EPS estimates ranging from ($1.51) to ($1.42). For the next year, analysts expect that the company will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.41) to ($0.76). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that follow Guardant Health.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.05. The firm had revenue of $36.66 million for the quarter, compared to analyst estimates of $32.12 million.

Several analysts recently issued reports on the company. Zacks Investment Research upgraded Garrett Motion from a “sell” rating to a “hold” rating in a report on Friday, May 10th. Canaccord Genuity dropped their target price on Yamana Gold from C$5.50 to C$4.25 in a report on Tuesday, April 16th. Cowen upped their target price on Guardant Health from $40.00 to $70.00 and gave the stock an “outperform” rating in a report on Wednesday, April 3rd. Bank of America set a $25.00 target price on Bed Bath & Beyond and gave the stock a “buy” rating in a report on Wednesday, April 10th. Finally, JPMorgan Chase & Co. set a €52.00 ($60.47) target price on Vonovia and gave the stock a “buy” rating in a report on Friday, May 10th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $83.50.

Shares of GH stock traded down $4.46 on Friday, hitting $85.05. 14,073 shares of the stock were exchanged, compared to its average volume of 714,905. The stock has a market cap of $7.63 billion and a price-to-earnings ratio of -30.38. The business has a 50-day moving average of $85.06. Guardant Health has a fifty-two week low of $27.04 and a fifty-two week high of $106.58.

In other Guardant Health news, Director Ian T. Clark sold 81,772 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $73.90, for a total value of $6,042,950.80. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Richard B. Lanman sold 1,690 shares of the company’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $80.00, for a total value of $135,200.00. The disclosure for this sale can be found here. Insiders have sold 975,338 shares of company stock worth $66,706,026 in the last quarter.

Large investors have recently added to or reduced their stakes in the business. Mascoma Wealth Management LLC bought a new stake in Guardant Health in the first quarter valued at approximately $54,000. Legal & General Group Plc bought a new stake in Guardant Health in the fourth quarter valued at approximately $85,000. Citigroup Inc. bought a new stake in Guardant Health in the fourth quarter valued at approximately $94,000. SG Americas Securities LLC bought a new position in shares of Guardant Health during the first quarter worth approximately $108,000. Finally, Victory Capital Management Inc. bought a new position in shares of Guardant Health during the fourth quarter worth approximately $124,000. Hedge funds and other institutional investors own 69.15% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Featured Story: How to Invest in a Bull Market

Get a free copy of the Zacks research report on Guardant Health (GH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit